Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Other Events
Item8.01 Other Events
On March7, 2017, Esperion Therapeutics,Inc. issued a press
release titled, Esperion Announces Initiation of Phase 2 Triplet
Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin (the
Press Release). A copy of the Press Release is filed herewith as
Exhibit99.1 and is incorporated herein by reference.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release dated March7, 2017. |
* * *
About Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors. Esperion Therapeutics, Inc. (NASDAQ:ESPR) Recent Trading Information
Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed its last trading session 00.00 at 31.28 with 786,571 shares trading hands.